A practical reference on GW501516: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-12-19 and is reviewed periodically as new material appears.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ | Nuclear receptor; not androgen receptor |
| Studied indications | Dyslipidemia; obesity; diabetes | Early clinical research; development discontinued |
| Rodent toxicity | Tumor formation in multiple tissues | Dose-dependent findings in some studies |
| Human approval | None | No approved therapeutic use |
| Typical analytical method | LC-MS/MS | Used for identity and quantification |
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
Human blood is typical of that of mammals, although the precise details concerning cell numbers, size, protein structure, and so on, vary somewhat between species. In non-mammalian vertebrates, however, there are some key differences:
Movshovitz-Attias, Dana; Cohen, William W. (2012). Alignment-HMM-based Extraction of Abbreviations from Biomedical Text. Montreal, Canada: NAACL. [1]. Davis, Neil M. (2014). Medical Abbreviations: 32,000 Conveniences at the Expense of Communication and Safety (15th ed.). Warminster, PA, USA: Neil M Davis Associates. ISBN 978-0-931431-15-9. Available online (by subscription) at MedAbbrev.com. Jablonski, Stanley (2008). Jablonski's Dictionary of Medical Acronyms and Abbreviations with CD-ROM (6th ed.). Philadelphia: Saunders. ISBN 978-1-4160-5899-1. Sloane, Sheila B. (1997). Medical Abbreviations & Eponyms (2nd ed.). Philadelphia: Saunders. ISBN 978-0-7216-7088-1.
During World War II, 1941–1945, India became the main base for the American China Burma India Theater (CBI) in the war against Japan. Tens of thousands of American servicemen arrived, bringing all sorts of advanced technology, and currency; they left in 1945. Serious tension erupted over American demands, led by U.S. President Franklin D. Roosevelt, that India be given independence, a proposition Churchill vehemently rejected. For years, Roosevelt encouraged British disengagement from India. The American position was based on an opposition to Europeans having colonies and a practical concern for the outcome of the war, and the expectation of a large American role in a post-independence era. Churchill threatened to resign if Roosevelt continued to push his case, causing Roosevelt to back down. Meanwhile, India became the main American staging base to fly aid to China. During World War II, the Panagarh Airport in Bengal Province of India was used as a supply transport airfield from 1942 to 1945 by the United States Army Air Forces Tenth Air Force and as a repair and maintenance depot for B-24 Liberator heavy bombers by Air Technical Service Command.
Sources: en.wikipedia.org
=== Lawsuit against WTVT === In 1997, the news division of WTVT (Channel 13), a Fox-owned station in Tampa, Florida, planned to air an investigative report by Steve Wilson and Jane Akre on the health risks associated with Monsanto's bovine growth hormone product, Posilac. Just before the story was to air, Fox received a letter from Monsanto saying the reporters were biased and that the story would damage the company. Akre stated that Wilson and she went through 83 rewrites over eight months. Negotiations broke down and both reporters were eventually fired. Wilson and Akre alleged the firing was for retaliation, while WTVT contended they were fired for insubordination. The reporters then sued Fox/WTVT in Florida state court under the state's whistleblower statute. In 2000, a Florida jury found that while no evidence showed Fox/WTVT had bowed to any pressure from Monsanto to alter the story, Akre, but not Wilson, was a whistleblower and was unjustly fired. She was awarded a $425,000 settlement. At the time of the decision, "the station claimed it did not bend to Monsanto's letter and wanted to air a hard-hitting story with a number of statements critical of Monsanto." Fox appealed the decision stating that under Florida law, a whistleblower can only act if "a law, rule, or regulation" has been broken and argued that the FCC's policy against distortions or misrepresentations presented as news did not fit that definition.
=== Faïences décoratives de la Vieille Turquie (Decorative Faience in Ancient Turkey) === Raymond published Faïences décoratives de la Vieille Turquie (Decorative Faience in Ancient Turkey) through the Paris publisher Albert Morancé; a little book that reproduced some of the plates from L'Art Islamique en Orient and introduced new ones.
== Personal life == On 6 March 2024, al-Burhan's son, Mohammed Fattah Burhan Rahman, was severely injured after his motorcycle collided with another vehicle in Ankara, Turkey. He died of his injuries on 3 May after spending nearly two months in intensive care.
=== Cholesterol clearance === Synthetic platelets are being explored for their potential in cholesterol clearance by facilitating the targeted removal of cholesterol from the bloodstream, offering a novel approach to treating hypercholesterolemia and preventing cardiovascular diseases. Elevated low-density lipoprotein cholesterol (LDL-C) is a key contributor to coronary heart disease, largely regulated by the interaction between LDL receptors (LDLR) and Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9). Since PCSK9 reduces LDLR availability, inhibiting it can enhance LDL-C clearance. To explore this, researchers designed platelet-mimicking nanoparticles to deliver siRNA targeting Pcsk9. These nanoparticles effectively lowered Pcsk9 mRNA levels by 66% in cell studies and reduced plasma LDL-C by 28% in animal models, without significantly altering high-density lipoprotein cholesterol (HDL-C) or triglycerides (TGs). This strategy demonstrates the potential of biomimetic nanoparticles for RNA-based therapies aimed at treating high cholesterol.
Sources: en.wikipedia.org
It targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not act primarily on androgen receptors. This distinction separates it from SARMs.
Rodent studies found dose-dependent tumors in several organs. The sponsor discontinued the program over cancer concerns. Human risk from long-term use remains unknown.
Controlled human endurance trials are lacking. Animal studies show increased exercise capacity under some conditions. Anecdotal reports are not equivalent to clinical evidence.
Cardarine is a common name for GW501516, a synthetic PPARδ agonist. It is not a steroid or a selective androgen receptor modulator. It was developed and studied as a research compound for metabolic pathways.